Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904851 · ClinicalTrials.gov registry record
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
A clinical trial of Peripheral Arterial Disease, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- 14,000
- Enrollment target
- 20
- Study locations
NCT01904851: Recruiting study of Peripheral Arterial Disease, sponsored by Baylor Research Institute.
NCT01904851 is a study of Peripheral Arterial Disease that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 14,000 participants, above the 4,029-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (247% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01904851, a study of Peripheral Arterial Disease, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- 14,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
XLPAD is an observational study designed to evaluate the effectiveness and use of stent and non-stent based therapies among PAD patients. The study will create a registry that will include entry of procedural and clinical follow-up information into an online data collection software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until 14,000 patients have been included. The primary objectives of this observational registry study are to: 1. Compare stent and non-stent based outcomes defined as a composite of symptom driven target vessel revascularization (TVR), unplanned surgical revascularization of the target limb and need for target limb amputation through 12 months post-index procedure (Primary efficacy endpoint) 2. Compare stent and non-stent based outcomes defined as a composite of causes such as: death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel revascularization (TVR) and unplanned surgical revascularization/amputation of the target limb through 12 months (Primary safety endpoint) 3. Compare stent and non-stent based change in walking distance, Rutherford category and/or ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical improvement endpoint) Approximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment in the observational study will be monitored in an effort to achieve at least 20% (and no more than 80%) of the population receiving stents as the initial treatment strategy. Follow-up visits by sites will be reported at 6 and 12 months after index procedure to collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures are not mandated by the registry protocol. Each site will be encouraged to enter follow-up information derived from clinically indicated follow-up visits. All events post-index procedure till the 7th month will be reported under the 6 month follow-up form and subsequent follow-up till t
Primary Outcome
Target Lesion or Vessel Revascularization or Surgical Revascularization/Amputation of Target Limb
Conditions Studied
Study Locations (20)
Texas
- Seton Heart Institute/ UT Austin - Austin
- Cardiothoracic and Vascular Surgeons - Austin
- Christus Sphon Hospital Corpus Christi-Shoreline - Corpus Christi
- North Texas Veteran Affairs Medical Center - Dallas
Ohio
- Cleveland Clinic - Cleveland
- Harrington Heart and Vascular Institute, University Hospitals - Cleveland
Oklahoma
- Oklahoma University Health Science Center - Oklahoma City
- Integris Heart Hospital - Oklahoma City
Arkansas
- Arkansas Heart Institute - Little Rock
Colorado
- Denver VAMC - Denver
Georgia
- Emory University - Atlanta
Illinois
- Loyola University Medical Center - Chicago
Indiana
- Indiana University Health Ball Memorial Hospital - Muncie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,000 participants |
| Start Date | 2013-01 |
| Est. Completion | 2033-01 |
What NCT01904851 shows while recruiting
NCT01904851 is an observational study that tracks outcomes without assigning an intervention. Its 14,000 participants enrollment target places it among the larger protocols in the corpus, above the 4,029-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (247% higher).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01904851 names 20 study sites across 15 states, led by Texas, Ohio, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01904851 about?
NCT01904851 is a clinical study titled "Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes". XLPAD is an observational study designed to evaluate the effectiveness and use of stent and non-stent based therapies among PAD patients. The study will create a registry that will include entry of procedural and clinical follow-up information into an online data collection software, REDCAP.Data ava...
What is the current status of trial NCT01904851?
This trial is currently recruiting. The enrollment target is 14,000 participants. The study started on 2013-01. Estimated completion is 2033-01.
What conditions does trial NCT01904851 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
Who is sponsoring clinical trial NCT01904851?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904851 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01904851's enrollment target sits among peer trials
14,000 2nd of 79 the highest of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia